Inventor · disambiguated record
Adrian Liam Gill
Also filed as: GILL ADRIAN · GILL ADRIAN L · GILL ADRIAN LIAM
41 granted patents·42 pending applications·358 citations·filing 2002–2025
98Inventor score
Files withREVOLUTION MEDICINES INC51ASTEX THERAPEUTICS LTD15BERDINI VALERIO7AMGEN INC1ASTRAZENECA AB1
Top patents by PatentIndex Score
83 records- 0198US12465643B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Granted Nov 11, 2025·1 cites·2 claims
- 0298US11952352B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Apr 9, 2024·6 cites·4 claims
- 0398US11608346B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Mar 21, 2023·9 cites·7 claims
- 0497US11566007B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jan 31, 2023·10 cites·2 claims
- 0596US12280113B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Apr 22, 2025·2 cites·4 claims
- 0696US11739074B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Aug 29, 2023·9 cites·2 claims
- 0795US12202845B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Jan 21, 2025·3 cites·6 claims
- 0895US11685749B2C26-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 27, 2023·5 cites·8 claims
- 0995US10980889B1C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Apr 20, 2021·8 cites·6 claims
- 1095US7385059B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2006·Granted Jun 10, 2008·33 cites·20 claims
- 1194US12252497B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 18, 2025·3 cites·10 claims
- 1294US12187746B2C26-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jan 7, 2025·5 cites·9 claims
- 1394US11690915B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2021·Granted Jul 4, 2023·9 cites·2 claims
- 1494US11168102B1Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Granted Nov 9, 2021·5 cites·18 claims
- 1594US10590090B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2018·Granted Mar 17, 2020·28 cites·50 claims
- 1694US8399442B2Pharmaceutical compoundsBERDINI VALERIO·Filed 2006·Granted Mar 19, 2013·62 cites·26 claims
- 1792US8895745B2Bicyclic heterocyclic compounds as FGFR inhibitorsBERDINI VALERIO·Filed 2007·Granted Nov 25, 2014·33 cites·20 claims
- 1891US8110573B2Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinasesBERDINI VALERIO·Filed 2005·Granted Feb 7, 2012·9 cites·17 claims
- 1990US7977477B2Benzimidazole derivatives and their use as protein kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2004·Granted Jul 12, 2011·35 cites·23 claims
- 2088US7825140B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2007·Granted Nov 2, 2010·7 cites·19 claims
- 2188US7745638B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2007·Granted Jun 29, 2010·8 cites·23 claims
- 2288US2025145643A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2387US8131527B1FGFR pharmacophore compoundsSAXTY GORDON·Filed 2007·Granted Mar 6, 2012·17 cites·47 claims
- 2486US12384750B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Granted Aug 12, 2025·0 cites·8 claims
- 2586US7625922B2Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compoundsCANCER REC TECH LTD·Filed 2005·Granted Dec 1, 2009·19 cites·44 claims
- 2685US8080666B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsBERDINI VALERIO·Filed 2010·Granted Dec 20, 2011·6 cites·19 claims
- 2783US8513276B2Imidazo[1,2-a]pyridine compounds for use in treating cancerBERDINI VALERIO·Filed 2007·Granted Aug 20, 2013·8 cites·16 claims
- 2882US12409225B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Granted Sep 9, 2025·0 cites·23 claims
- 2982US12403196B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Granted Sep 2, 2025·0 cites·4 claims
- 3080US2025255964A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 3180US2025319187A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 3279US8778936B2Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinasesBERDINI VALERIO·Filed 2011·Granted Jul 15, 2014·2 cites·20 claims
- 3379US2023106174A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Application pending·0 cites
- 3478US6538015B1Anti-HIV pyrazole derivativesHOFFMANN LA ROCHE·Filed 2002·Granted Mar 25, 2003·9 cites·9 claims
- 3577US11673896B2Pyridine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Jun 13, 2023·1 cites·16 claims
- 3677US8779147B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsBERDINI VALERIO·Filed 2011·Granted Jul 15, 2014·2 cites·14 claims
- 3776US2025074923A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3876US2025361245A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3975US11739093B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Aug 29, 2023·1 cites·18 claims
- 4075US2025051306A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4175US2023374035A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 4273US12258366B2Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 25, 2025·0 cites·14 claims
- 4371US12365688B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jul 22, 2025·0 cites·36 claims
- 4471US2024139185A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 4570US2024067636A1Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 4670US2024101577A1Polycyclic compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 4770US2024092795A1Pyridine compounds as allosteric shp2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 4869US2025368661A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 4968US2019336609A1C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR InhibitorsREVOLUTION MEDICINES INC·Filed 2019·Application pending·0 cites
- 5067US7737152B26-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compoundsWELLCOME TRUST LTD·Filed 2005·Granted Jun 15, 2010·3 cites·27 claims
Showing the top 50 of 83 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Adrian Liam Gill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →